Pharmaceutical companies have vigorously engaged in research and development (R&D) activities to discover future foods. 7 out of 10 major traditional pharmaceutical companies increased their R&D investment compared to last year. R&D expenditures have increased significantly due to the development of new drugs and the introduction of new R&D pipelines. In particular, R&D investments by GC Biopharma and JW Pharmaceuticals soared.

According to the Financial Supervisory Service on the 25th, the R&D investment made by 20 major biopharmaceutical companies in Q1 totaled up to KRW 390.6 billion, which was 13.4% increase from the previous year. The top 20 sales of traditional pharmaceutical companies that submitted